Best Small Cap Stocks to Trade

Small Cap Stock Alerts in Real Time | No one provides consistent winners like Broad Street!

May 02 2016

Corporate, Pipeline and Financial Updates

See feature articles below:

About Broad Street Alerts:
Big opportunities in Small Cap’s

Broad Street Alerts recent profiles and track record, 217% in verifiable potential gains for our members on the last 4 small cap alerts alone!
February 10th, 2016- (NASDAQ: BONT) opened $1.65/share hit a high of $3.00/share within 30 days our member potential gains- 83%
March 7th, 2016-(NYSE-MKT: FSI) opened at .91/share and hit 1.10/share within 5 days for gains of 21% for our members.
March 24th, 2016- (NASDAQ: ICLD) opened at $.77/share it a high of $1.15/share within 2 days for gains of 49% for our members.
April 11th, 2016 – (NASDAQ: FNJN) called at $1.07/share hit $1.76/share in 3 days for 64% gains for our members.

These are numbers that make traders drool. Any trader in any market would fall all over themselves to see numbers like this. So if you’ve been on the fence, perhaps it’s time to start doing some research and verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest of the small-cap newsletters as the best in business.
We know with a large following comes a large responsibility as we have everyone from institutional investors to the beginner following our profiled securities in our newsletters. This is something we take very seriously always seeking small cap growth companies that have both near and long-term potential for our members.
***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our VIP SMS/text alert service for free, simply text the word “Alerts” to the phone number 25827 from your cell phone.

Report for: Affimed N.V.

 

Heidelberg, Germany, March 30, 2016 – Affimed N.V. (Nasdaq: AFMD), a clinical stage
biopharmaceutical company focused on discovering and developing highly targeted cancer
immunotherapies, today reported financial results for the fourth quarter and year ended December
31, 2015.
“2015 was a formative year for Affimed,” said Dr. Adi Hoess, CEO of Affimed. “Through the
continuous support of our investors we were able to broaden the development of our NK- and Tcell-recruiting
immunotherapies. We have continued to successfully advance our clinical and
preclinical pipeline and, in particular, we have made significant headway with our lead candidate
AFM13 toward development as both mono- and combination therapy.”
Corporate Highlights
Affimed closed two major financings in 2015. In May, the Company completed a follow-on
offering on the Nasdaq Global Market, raising a total of approximately US $37.5 million
(€33.5 million) in net proceeds and in October, Affimed raised $21.8 million (€19.1 million)
from Aeris Capital, a long-term existing shareholder. Proceeds from these two transactions
are expected to fund operations, including clinical development and further discovery and
early development activities, until the first quarter of 2018.
Together with its collaboration partner, Stanford University, Affimed presented evidence of
the synergistic effect of the Company’s lead candidate, AFM13, a bispecific CD30/CD16A
NK-cell-engaging TandAb, in combination with checkpoint modulators including checkpoint
inhibitor anti PD-1, at the American Society of Clinical Oncology (ASCO) and American
Society of Hematology (ASH) annual meetings in May and December, respectively. Data
from four individual studies of in vivo PDX models with human CD30-positive Hodgkin
lymphoma (HL) tumors consistently showed that combination therapy of AFM13 with anti
PD-1, but not treatment with anti PD-1 alone, rapidly enriches the tumor microenvironment
with NK-cells, followed by subsequent tumor infiltration by T-cells as well as substantially

elevated levels of cytokines within the tumor, indicating AFM13’s unique ability to trigger
the body’s natural immune cascade.
The Company established operations in the United States and strengthened its US
presence with the addition of Caroline Stewart (Head of Investor Relations) and Dr. Oscar
Kashala (Vice President, Medical, US) in June, and of Andrew Curtis (Head of Corporate
Strategy and Business Development) in December.In June, Affimed formalized a Scientific Advisory Board comprising renowned scientists
and physicians from a broad range of areas relevant to Affimed’s approach including
immuno-oncology, NK-cells, lymphoma and leukemia.Affimed’s wholly owned subsidiary, AbCheck, and Pierre Fabre Pharmaceuticals entered
into a strategic research partnership in the field of human antibody discovery and
optimization in June, expanding their ongoing collaboration. Together with its partner
Distributed Bio, Inc., AbCheck developed a novel, highly potent technology enabling
accelerated humanization of rabbit antibodies.
Affimed was added to two performance indices in 2015, the Russell 2000 Index® in June
and the NASDAQ Biotechnology Index® in December, respectively.
In early 2016, Affimed strengthened its management team through the addition of Dr. Joerg
Windisch as Chief Operating Officer. With his broad expertise in regulatory affairs, quality
control and project management and his proven track record in the development and
manufacturing of marketed biologics, Dr. Windisch will support the Company’s expanding
clinical pipeline.
Affimed announced the addition of Dr. Bernhard Ehmer to its Supervisory Board in January
2016. Dr. Ehmer is a seasoned expert in the industry with extensive international general
management and clinical development experience in biopharmaceuticals.
In January 2016, Affimed entered into a collaboration with Merck to evaluate AFM13 in
combination with Merck’s KEYTRUDA® in relapsed/refractory HL.

Pipeline Updates
AFM13
In the second quarter of 2015, a Phase 2a clinical trial in relapsed/refractory HL was
initiated for the Company’s lead candidate, AFM13, a bispecific CD30/CD16A NK-cellengaging
TandAb. Patient enrollment is ongoing and interim data are expected in the
second quarter of 2016, with primary endpoint data anticipated to be reported by the end
of 2016.
An additional Phase 1b trial in relapsed/refractory HL patients with AFM13 in combination
with Merck’s anti PD-1 checkpoint inhibitor KEYTRUDA® (pembrolizumab), designed to
establish a dosing regimen for the combination therapy and assess its safety and efficacy
is on track to be initiated in the first half of 2016.
Affimed is supporting an investigator-sponsored translational Phase 1b/2a trial in CD30-
positive lymphoma with cutaneous manifestation in collaboration with Columbia University
for which Columbia submitted an IND to the FDA that has since become effective.
AFM11
For Affimed’s second candidate, AFM11, a bispecific CD19/CD3 T-cell-engaging TandAb,
patient enrollment continued into the amended Phase 1 study in non-Hodgkin lymphoma
(NHL). The Company’s amended study protocol allows for investigation of less frequent
dosing of AFM11, benefiting the overall development of AFM11. Based on the revised
protocol, Affimed expects to report first data by the end of 2016.
Affimed will investigate AFM11 in acute lymphocytic leukemia (ALL) in a separate Phase 1
clinical trial rather than sequentially, which is anticipated to help optimize

Preclinical programs
In May 2015, Affimed reported pre-clinical data on its collaborative CD33/CD3 program for
the treatment of acute myeloid leukemia (AML) with Amphivena/Janssen at the ASCO 2015
Annual Meeting. This program validates the robustness of Affimed’s TandAb platform, and
the data demonstrated corroborative evidence of direct correlation between binding affinity
and potency.
Affimed presented data at several scientific conferences in 2015 showing high specificity
and cytotoxic potency of its EGFRvIII/CD3-targeting T-cell TandAb AFM21 and its
EGFRvIII/CD16A-targeting NK-cell TandAb AFM22.
Affimed is also developing AFM24, an NK-cell-engaging TandAb targeting EGFR-wild
type, which is expressed by a variety of solid tumors, such as colorectal cancer (CRC),
non-small cell lung cancer (NSCLC) or squamous cell carcinomas of the head and neck
(SCCHN). Our data suggest that EGFR/CD16A TandAbs are suited to overcome the
intrinsic or acquired resistance to other EGFR-targeting treatments such as tyrosine
kinase inhibitors or monoclonal antibodies, which has been observed in a large number of
patients.
Financial Highlights
(Figures for the fourth quarter of 2015 and 2014 represent unaudited figures)
Cash and cash equivalents totaled €76.7 million as of December 31, 2015 compared to €39.7
million as of December 31, 2014. The increase was primarily attributable to the completion of
Affimed’s follow-on offering of its common shares on May 12, 2015, and the sale of additional
shares to Aeris Capital on October 9, 2015.
Net cash used in operating activities for the fourth quarter of 2015 was €4.0 million compared to
€5.4 million for the fourth quarter of 2014. Net cash used in operating activities was €18.5 million
for the twelve months ended December 31, 2015 compared to €10.5 million for the twelve months
ended December 31, 2014. The year-over-year increase was primarily related to higher cash
expenditure for research and development (R&D) in connection with our development and
collaboration programs and to higher general and administrative expenses.

Financial Highlights
(Figures for the fourth quarter of 2015 and 2014 represent unaudited figures)
Cash and cash equivalents totaled €76.7 million as of December 31, 2015 compared to €39.7
million as of December 31, 2014. The increase was primarily attributable to the completion of
Affimed’s follow-on offering of its common shares on May 12, 2015, and the sale of additional
shares to Aeris Capital on October 9, 2015.
Net cash used in operating activities for the fourth quarter of 2015 was €4.0 million compared to
€5.4 million for the fourth quarter of 2014. Net cash used in operating activities was €18.5 million
for the twelve months ended December 31, 2015 compared to €10.5 million for the twelve months
ended December 31, 2014. The year-over-year increase was primarily related to higher cash
expenditure for research and development (R&D) in connection with our development and
collaboration programs and to higher general and administrative expenses.
Revenue for the fourth quarter of 2015 was €1.7 million compared to €0.1 million for the fourth
quarter of 2014 due to revenue earned under the Amphivena collaboration in the 2015 period.
Revenue for the full year 2015 was €7.6 million compared to €3.4 million for the full year 2014.
Revenue in both periods was primarily derived from Affimed’s collaborations with Amphivena and
the LLS as well as from third party services rendered by AbCheck.
R&D expenses for the fourth quarter of 2015 were €7.0 million compared to €4.1 million for the
fourth quarter of 2014. For the full year 2015, R&D expenses were €22.0 million compared to €9.6
million for the full year 2014. The increase was primarily related to higher expenses for AFM13,
other preclinical programs and infrastructure.
G&A expenses for the fourth quarter of 2015 were €2.0 million compared to €1.7 million for the
fourth quarter of 2014. For the full year 2015, G&A expenses were €7.5 million compared to €2.3
million for the full year 2014. The increase was primarily related to a credit to the share-based
payment expense resulting from a re-measurement gain at consummation of the IPO in 2014.
Net loss for the fourth quarter of 2015 was €6.3 million, or €0.19 per common share, compared to
a net loss of €5.3 million, or €0.22 per common share, for the fourth quarter of 2014. Net loss for
the full year 2015 was €20.2 million, or €0.71 per common share, compared to a loss of €0.3
million, or €0.01 per common share, for the full year 2014. The increase in net loss for the full year
2015 is primarily related to non-operational and non-cash effects in 2014 upon the corporate
reorganization at the time of the IPO in September 2014 as well as to increased spending on
infrastructure and on research and development commensurate with the ramp-up of the clinical
trials for our lead product candidate AFM13 and for our preclinical programs in 2015. Additional
information regarding these results is included in the notes to the consolidated financial statements
as of December 31, 2015 and “Item 5. Operating and Financial Review and Prospects,” which will
be included in Affimed’s Annual Report on Form 20-F as filed with the SEC.

Source – Affimed Press Release
Broad street alerts has not been compensated for the mention of any publicly traded companies in this article nor do we own positions in any of the companies in this article.

Broad Street Alerts was previously compensated eighteen thousand five hundred dollars by star media llc for the mention of FNJN however, that contract has expired.
Stock market

Hot small cap stocks

small cap stock picks

Biotech stocks

FDA approval stocks

FDA calendar

Trade stocks

Become a day trader

Day trade stocks for a living

PDUFA date set

micro cap stocks

Best stocks 2016

Hottest small cap stocks

Best stock picks

Who to follow for stock picks

Apple news stock picks

Stock picks on apple news

Written by broadAdmin · Categorized: Uncategorized

Privacy Policy and Disclaimer

Transparency is very important to us.

Please view our full privacy policy and disclaimer below.

 

 

 

Privacy Policy and Disclaimer
Your Consent
By using our site, you consent to our online privacy policy and disclaimer.
Do we disclose any information to outside parties?
We do not sell your information to anyone.
What information do we collect?
We collect information from you when you subscribe to our newsletter or fill out a form on one of our social platforms. This includes your email address and or mobile phone number.
When registering on our site, as appropriate, you may be asked to enter your: e-mail address and or mobile number.
What do we use your information for?
When we collect your email or mobile number it is used for one purpose to send you the information you requested about small cap stocks. Please read our disclaimer carefully before viewing our emails.
Your information, whether public or private, will not be sold, exchanged, transferred, or given to any other company for any reason, other than our CRM providers for the express purpose of delivering the information on stocks that you requested.
We send periodic emails.
The email address you provide may be used to send you information, the small cap stock reports you requested, respond to inquiries, and/or other requests or questions.
How do we protect your information?
We implement a variety of security measures to maintain the safety of your personal information when you enter, submit, your email address. We use secure third parties to send email and SMS messages to you.
Because we value your privacy, we have taken the necessary precautions to be in compliance with the California Online Privacy Protection Act.
Online Privacy Policy Policy
This online privacy policy applies to information collected through our website and social media platforms.
Contacting Us
If there are any questions regarding this privacy policy or disclaimer you may reply to this email.
Disclaimer
BroadStreetAlerts. com is a wholly owned subsidiary of Small Cap Specialists LLC, herein referred to as SCS LLC.
This website / media webpage is owned, operated, and edited by Small Cap Specialists LLC. Any wording found on this website / media webpage or disclaimer referencing to “I” or “we” or “our” or “SCS LLC” refers to Small Cap Specialists LLC. This website / media webpage is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to market and promote public companies. By reading our website / media webpage you agree to the terms of our disclaimer, which are subject to change at any time.
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use. SCS LLC’s business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our Websites, Email, SMS, Push Notifications, Influencers, Social Media Postings, Ticker Tags, Press Releases, Online or Phone Interviews, Podcasts, Videos, Audio Ads, Banner Ads, Native Ads, Responsive Ads. This compensation is a major conflict of interest in our ability to be unbiased regarding. Therefore, this communication should be viewed as a commercial advertisement only. Note, we periodically conduct interviews and issue stock alerts that we are not compensated for, these are purely for the purpose of building our brands. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct.
Please Note: SCS LLC and its employees are not a registered investment advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold SCS LLC, its operator’s , owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information in our website / media webpage is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, SCS LLC often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. Some of our claims regarding gains could be based on intra-day, pre-market and after-hours trading data.
All information on featured companies is provided by the companies profiled or is available from public sources and SCS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead SCS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D.
SCS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and SCS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in small and micro-cap growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.
In preparing this publication, SCS LLC has relied upon information supplied by its customers, publicly available information, and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, SCS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement.
SCS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.
SCS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA. SCS LLC is not a Broker/Dealer and does not engage in high frequency trading.

 

 

Most Publicly Traded Companies Engage in Some Form of Paid Media, Investor Relations and Advertising. 

Copyright © 2023 · Broad Street Alerts · All Rights Reserved

Manage Cookie Consent
We use cookies to optimize our website and your experience.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage vendors Read more about these purposes
View preferences
{title} {title} {title}